Hence, by targeting PSMA, which is overexpressed in cancer cells, and FAP, which is overexpressed in tumor stroma, we hypothesized that it would potentially increase the lesion detection rate and tumor retention in prostate cancer patients. The gene discussed is FOLH1; the disease is Familial prostate cancer.